Aug Reason 5 O O
22 Reason 5 O O
(Reuters) Reason 5 O O
- Reason 5 O O
The Reason 5 O O
U.S. Reason 5 O O
government Reason 5 O O
said Reason 5 O O
on Reason 5 O O
Tuesday Reason 5 O O
it Reason 5 O O
had Reason 5 O O
awarded Reason 5 O O
$1.4 Reason 5 O O
billion Reason 5 O O
for Reason 5 O O
the Reason 5 O O
development Reason 5 O O
of Reason 5 O O
new Reason 5 O O
therapies Reason 5 O O
and Reason 5 O O
vaccines Reason 5 O O
against Reason 5 O O
COVID-19, Reason 5 O O
including Reason 5 O O
a Reason 5 O O
$326 Reason 5 O O
million Reason 5 O O
contract Reason 5 O O
with Reason 5 O O
Regeneron Reason 5 O O
Pharmaceuticals Reason 5 O O
for Reason 5 O O
a Reason 5 O O
next-generation Reason 5 O O
antibody Reason 5 O O
therapy Reason 5 O O
for Reason 5 O O
prevention Reason 5 O O
of Reason 5 O O
infections. Reason 5 O O
The O O O O
funding O O O O
to O O O O
Regeneron O O O O
is O O O O
a O O O O
part O O O O
of O O O O
a O O O O
$5 O O O O
billion O O O O
initiative O O O O
dubbed O O O O
"Project O O O O
NextGen" O O O O
by O O O O
the O O O O
U.S. O O O O
Department O O O O
of O O O O
Health O O O O
and O O O O
Human O O O O
Services O O O O
(HHS). O O O O
Regeneron Reason 2 O O
had Reason 2 O O
earlier Reason 2 O O
developed Reason 2 O O
a Reason 2 O O
monoclonal Reason 2 O O
antibody Reason 2 O O
therapy Reason 2 O O
against Reason 2 O O
COVID, Reason 2 O O
which Reason 2 O O
was Reason 2 O O
authorized Reason 2 O O
by Reason 2 O O
the Reason 2 O O
U.S. Reason 2 O O
Food Reason 2 O O
and Reason 2 O O
Drug Reason 2 O O
Administration Reason 2 O O
in Reason 2 O O
November Reason 2 O O
2020, Reason 2 O O
but Reason 2 O O
its Reason 2 O O
use Reason 2 O O
was Reason 2 O O
limited Reason 2 O O
early Reason 2 O O
last Reason 2 O O
year Reason 2 O O
after Reason 2 O O
it Reason 2 O O
was Reason 2 O O
found Reason 2 O O
to Reason 2 O O
be Reason 2 O O
unlikely Reason 2 O O
to Reason 2 O O
work Reason 2 O O
against Reason 2 O O
the Reason 2 O O
Omicron Reason 2 O O
variant. Reason 2 O O
The O O O O
funding O O O O
also O O O O
includes O O O O
$1 O O O O
billion O O O O
for O O O O
four O O O O
mid-stage O O O O
clinical O O O O
trials O O O O
of O O O O
new O O O O
COVID O O O O
vaccines, O O O O
and O O O O
$100 O O O O
million O O O O
to O O O O
Global O O O O
Health O O O O
Investment O O O O
Corp O O O O
- O O O O
a O O O O
non-profit O O O O
organization O O O O
that O O O O
invests O O O O
in O O O O
new O O O O
technologies O O O O
that O O O O
will O O O O
accelerate O O O O
responses O O O O
to O O O O
diseases. O O O O
(Reporting O O O O
by O O O O
Pratik O O O O
Jain O O O O
in O O O O
Bengaluru; O O O O
Editing O O O O
by O O O O
Maju O O O O
Samuel) O O O O
